Oblita Therapeutics

Foundation date

08/03/2016

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Oblita Therapeutics is a global health research & development start-up company. Our goal is to close current therapeutic gaps and improve the quality of life of those suffering from “forgotten” (neglected) diseases. Oblita Therapeutics’ lead program is focused on the development of a new drug (D121) to treat leishmaniasis (starting phase II). We have convincing preclinical results on the effectiveness of D121 against Cryptosporidium Parvum infection, Chagas Disease, and Fungal Infections.

Latest news

  • Researchers unravel complexities of Alzheimer’s disease in protein fragments and plaque diversity

    10 hours ago

  • New software from UHasselt and ZEISS shows in sharp detail how biomolecules move in cells.

    1 day ago

  • Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

    1 day ago